Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CSF biomarkers in different phenotypes of Parkinson disease.

Journal of neural transmission (Vienna, Austria : 1996) - 1 Apr 2012

Jellinger Kurt A

Abstract excerpt

CSF biomarker studies were performed in 6 patients each with tremor-dominant (TD) and non-tremor-dominant (NT) Parkinson disease (PD) patients, 27 Alzheimer disease (AD) and 17 age-matched controls. In both NT-PD and AD patients total tau levels and the cortex tau/Aβ-42 were significantly increased compared to both TD-PD patients and controls (p < 0.01). These data in a small cohort confirm previous studies,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Parkinson Disease

Share to Peptide Fragments

Share to tau Proteins

Share to Tremor

Source

Identifiers

PMID: 22065209
DOI: 10.1007/s00702-011-0736-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF biomarkers in different phenotypes of Parkinson disease.PMID 22065209Read ↗

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.Semantic proximity Read ↗

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Semantic proximity Read ↗

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.Semantic proximity Read ↗

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism SyndromesSemantic proximity Read ↗

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.Semantic proximity Read ↗

Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.Semantic proximity Read ↗

Cerebrospinal fluid biomarker for Parkinson's disease: An overviewSemantic proximity Read ↗

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.Semantic proximity Read ↗

CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's DiseaseSemantic proximity Read ↗

High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease.Semantic proximity Read ↗

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson diseaseSemantic proximity Read ↗

Cerebrospinal fluid profile, including α-Synuclein seeding activity, of p.A53T SNCA mutation carriers: Data from the PPMI StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.